This inventor holds 1 USPTO granted patent and 1 published patent application. Top assignee: Ucb Pharma, S.a.. Active years: 2009.
Company Filing History:
Years Active: 2009
Title: Thierry Kogej: Innovator in Pharmaceutical Chemistry
Introduction
Thierry Kogej is a notable inventor based in Gothenburg, Sweden. He has made significant contributions to the field of pharmaceutical chemistry, particularly in the development of compounds that target inflammatory diseases.
Latest Patents
Kogej holds a patent for 2,6-quinolinyl and 2,6-naphthyl derivatives, which are processes for preparing these compounds and their uses as VLA-4 inhibitors. This invention addresses the need for effective treatments for VLA-4 dependent inflammatory diseases, including asthma, allergic rhinitis, and rheumatoid arthritis. The patent outlines the chemical formula (I), where X can be either N or CH, highlighting the innovative nature of his work.
Career Highlights
Kogej is currently associated with Ucb Pharma, S.A., where he continues to advance his research in pharmaceutical applications. His work has the potential to impact the treatment of various inflammatory conditions, showcasing his dedication to improving patient outcomes.
Collaborations
Throughout his career, Kogej has collaborated with esteemed colleagues such as Gerald Guillaumet and Luc Quere. These partnerships have fostered a collaborative environment that enhances the innovation process.
Conclusion
Thierry Kogej's contributions to pharmaceutical chemistry, particularly through his patent on VLA-4 inhibitors, demonstrate his commitment to addressing critical health challenges. His work continues to pave the way for advancements in the treatment of inflammatory diseases.